Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5 [Benefici del paracalcitolo iniettabile sulla morbilita cardiaca indotta da insufficienza renale in soggetti con nefropatia cronica di stadio 5]

Trial Profile

Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5 [Benefici del paracalcitolo iniettabile sulla morbilita cardiaca indotta da insufficienza renale in soggetti con nefropatia cronica di stadio 5]

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paricalcitol (Primary)
  • Indications Kidney disorders
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Registrational
  • Acronyms PRIMO-II
  • Sponsors Abbott Laboratories

Most Recent Events

  • 22 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
  • 27 Feb 2009 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top